Solventum (SOLV) FY2025 10-K Annual Report
Solventum (SOLV) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 27, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Solventum FY2025 10-K Analysis
Business Overview
- • Global healthcare company (~20,000 employees, ~$0 revenue figures disclosed) across three segments: MedSurg 57.9%, Health Information Systems 16.3%, Dental Solutions 16.2% of 2025 sales
- • Two major portfolio moves in 2025: acquired Acera Surgical (bioscience, adds synthetic tissue matrices) and divested Purification & Filtration business to Thermo Fisher Scientific
- • Still separating from 3M parent — actively transitioning off 3M infrastructure under Transition and Distribution Agreement and Transition Contract Manufacturing Agreement, a key ongoing operational risk
- • R&D team of ~2,000 employees; sales presence in 90+ countries with ~40% of workforce having 10+ years tenure, signaling stable legacy talent base during post-spin transition
- • U.S. Supreme Court ruled Feb 20, 2026 that IEEPA does not authorize presidential tariffs — Solventum explicitly flagged potential tariff recovery but stated financial impact "cannot be reasonably estimated," a rare forward-looking legal disclosure embedded in the business section
Management Discussion & Analysis
- • Revenue $8,325M, up 0.9% YoY ($71M increase); organic growth 3.3%, offset by -3.0% divestiture impact from Purification & Filtration sale
- • Operating margin 26.2% vs 12.6% in 2024 (includes $1.5B gain on P&F sale); SG&A 37.0% vs 33.7%; R&D 8.9% vs 9.4%
- • Best segment: Health Information Systems, operating margin 36.5% vs 33.0%, sales +4.1% to $1,360M; worst: MedSurg margin 16.8% vs 19.1%, despite 3.9% sales growth to $4,817M
- • Investing activities $2,797M inflow (vs -$380M in 2024) driven by ~$4B P&F sale proceeds; financing outflows -$3,057M including $2.0B senior note repayment and $1,070M term loan repayments; cash position $878M at year-end
- • Key risks: tariff impact ~$55M on product costs, ongoing 3M supply agreement mark-ups, debt servicing burden, and brand transition from 3M; no explicit forward guidance provided
Risk Factors
- • 3M sole-source supplier for materials tied to ~$3B revenue (FY2025); ~$2B from proprietary material with no identified substitute or internal manufacturing capability
- • $5B outstanding debt post-spin as of Dec 31, 2025; constrains capital allocation, raises downgrade risk, and limits strategic flexibility
- • U.S.-China trade tensions and tariffs actively impacting Solventum and suppliers; further escalation cited as material risk to global operations
- • AI-enabled new entrants threatening Health Information Systems segment specifically; failure to match competitor AI integration risks customer loss
- • PFAS indemnification from 3M expires after 2025 product sales; ongoing PFAS use in components (wound therapy, temp management devices) creates unindemnified regulatory and litigation exposure
Solventum FY2025 Key Financial MetricsXBRL
Revenue
$8.3B
▲ +0.9% YoY
Net Income
$1.6B
▲ +224.8% YoY
Gross Margin
53.5%
▼ -218bp YoY
Operating Margin
26.2%
▲ +1365bp YoY
Net Margin
18.7%
▲ +1289bp YoY
ROE
30.8%
▲ +1463bp YoY
Total Assets
$14.3B
▼ -1.1% YoY
EPS (Diluted)
$8.88
▲ +221.7% YoY
Operating Cash Flow
$369M
▼ -68.9% YoY
Source: XBRL data from Solventum FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Solventum Annual Reports
Get deeper insights on Solventum
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.